ABSCF Stock - AB Science S.A.
Unlock GoAI Insights for ABSCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.07M | $970,000 | $958,000 | $1.61M | $1.58M |
| Gross Profit | $1.25M | $587,000 | $927,000 | $1.50M | $1.51M |
| Gross Margin | 116.4% | 60.5% | 96.8% | 93.1% | 95.6% |
| Operating Income | $-6,083,000 | $-13,429,000 | $-15,937,000 | $-13,808,000 | $-14,749,000 |
| Net Income | $-7,831,000 | $-11,985,000 | $-13,615,000 | $-14,463,000 | $-15,045,000 |
| Net Margin | -730.5% | -1235.6% | -1421.2% | -900.0% | -950.4% |
| EPS | $-0.15 | $-0.24 | $-0.29 | $-0.30 | $-0.34 |
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Visit WebsiteEarnings History & Surprises
ABSCFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q2 2025 | May 12, 2025 | — | $-0.07 | — | — |
Q4 2024 | Oct 10, 2024 | — | $-0.09 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.03 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.24 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.15 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.16 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.24 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.12 | — | — |
Q4 2020 | Dec 31, 2020 | $-0.21 | $-0.17 | +19.8% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | $-0.18 | $-0.25 | -41.8% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | $-0.29 | $-0.24 | +19.3% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | $-0.40 | $-0.39 | +1.9% | ✓ BEAT |
Q4 2018 | Dec 31, 2018 | — | $-0.44 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.34 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.39 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.42 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.38 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.47 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.43 | — | — |
Latest News
Frequently Asked Questions about ABSCF
What is ABSCF's current stock price?
What is the analyst price target for ABSCF?
What sector is AB Science S.A. in?
What is ABSCF's market cap?
Does ABSCF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ABSCF for comparison